Post by PharmaShots

The NMPA grants conditional approval to HUTCHMED’s Orpathys (savolitinib) for MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma, offering a targeted option for patients with poor prognosis Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #hutchmed #orpathys #savolitinib #gastriccancer #metamplification #pii #astrazeneca #regulatory #oncology #precisionmedicine https://lnkd.in/dgcqapDC